In 2019, the Accelerated Access Collaborative (AAC) agreed to establish an ambitious programme of work to address the barriers to NHS adoption of early-stage innovative products.
Two emerging and promising categories of innovative treatment, Advanced Medicinal Therapy Products (ATMPs) and Histology Independent Therapies (HITs) were selected for AAC support because they both required system wide changes to smooth their introduction into the NHS. Addressing the barriers for these two categories of innovation at a system level would in turn pave the way for future innovations.
These innovative treatments are already available within the NHS in small numbers. The introduction of both ATMPs and HITs requires new ways of working in the healthcare system. AAC partners, including NHS England, Association of the British Pharmaceutical Industry (ABPI), Cell and Gene Therapy Catapult, National Institute for Health and Care Excellence (NICE), Medicines Health and Regulatory Agency (MHRA), have been working collaboratively to ensure the healthcare system is ready to introduce more of these innovative treatments to ensure we can get the most promising new treatments to patients faster.
Watch the animations below to find out how the NHS is working with its partners to support the availability of ATMPs and HITs.